A Study of AMDX-2011P in Participants With CAA

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Amydis Inc.
Study ID
NCT05709314
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cerebral Amyloid Angiopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AMDX-2011P — DRUG
    AMDX-2011P single bolus injection intravenous for diagnostic review

Study Details

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).

Key Dates

Start date
Jul 9, 2024
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: AMDX-2011P 100 mg
    AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review

Primary Outcome Measure

AMDX-2011P Adverse Events Profile [ Time Frame: 8 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Associated Retina ConsultantsPhoenixArizona85020
Mallory Mintert
[email protected]

Find similar trials in Phoenix, AZ

By research site
Associated Retina Consultants· Phoenix, AZ

Related Studies